This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

SuperB Trial: SUrgical Versus PERcutaneous Bypass (SuperB)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Michel Reijnen, Rijnstate Hospital
ClinicalTrials.gov Identifier:
NCT01220245
First received: October 11, 2010
Last updated: April 10, 2017
Last verified: April 2017
  Purpose
In this multicentre Randomized Clinical Trial, the heparin-bonded endoluminal bypass will be compared to the surgical venous femoro-popliteal bypass, based on the non-inferiority principle for the patency. Besides equal patency, an improved quality of life is expected. Recruitment will take the first two years and patients will be followed during five years. Patients with an indication for surgical bypass, classified category 3-6 with a >50% stenosis or occlusion of the SFA over >/=10 cm in length will be included. At least one crural artery should be patent without significant lesions.

Condition Intervention
Cardiovascular Diseases Procedure: Heparin-bonded ePTFE endoluminal fem-pop bypass Procedure: Surgical femoro-popliteal bypass.

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Heparin-bonded Endoluminal Versus Surgical Femoropopliteal Bypass; a Multicentre Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Michel Reijnen, Rijnstate Hospital:

Primary Outcome Measures:
  • Primary (and -assisted) patency [ Time Frame: 5 years ]
  • Quality of life [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Secondary patency [ Time Frame: 5 years ]
  • Complications [ Time Frame: 5 years ]
  • Clinical improvement [ Time Frame: 5 years ]
  • Re-intervention [ Time Frame: 5 years ]
  • Target lesion revascularisation [ Time Frame: 5 years ]

Estimated Enrollment: 126
Study Start Date: October 2010
Estimated Study Completion Date: July 2020
Estimated Primary Completion Date: July 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Heparin-bonded endoluminal fempop bypass
Heparin-bonded ePTFE endoluminal femoro-popliteal bypass versus surgical femoro-popliteal bypass
Procedure: Heparin-bonded ePTFE endoluminal fem-pop bypass
Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass
Active Comparator: Surgical femoro-popliteal bypass
Surgical femoro-popliteal bypass.
Procedure: Surgical femoro-popliteal bypass.
Surgical femoro-popliteal bypass.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age over 18 years
  • Informed consent
  • Novo stenosis, restenosis >50% or occlusion of the native SFA, all > 10cm in length
  • Patent popliteal artery at the upper margin of the patella to the trifurcation
  • Diameter native SFA and popliteal artery are 5.0-7.5 mm
  • Indication for surgical bypass
  • Distal run-off at least one crural artery without significant stenosis
  • Ankle-brachial index (ABI) at rest < 0.8 in the study limb prior to procedure

Exclusion Criteria:

  • Patient unsuitable for administration of contrast agent
  • Pregnancy
  • Dementia or altered mental status that would prohibit giving conscious informed consent
  • Need for adjunctive major surgical or vascular procedures within one month
  • Untreated flow-limiting aortoiliac occlusive disease
  • Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment
  • Femoral or popliteal aneurysm of target vessel
  • Non-arthrotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
  • Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancies, dementia etc.) or other medical condition that would preclude compliance with study protocol
  • Major distal amputation (above the transmetatarsal) in the study limb
  • Any previously known coagulation disorder, including hypercoagulability
  • Contraindication to anticoagulation or antiplatelet therapy
  • Known allergies to stent/stent-graft components
  • History of prior life-threatening reaction to contrast agent
  • Patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
  • Planned surgical procedure or major amputation to occur after enrollment of the patient
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01220245

Locations
Netherlands
Nij Smellinghe Hospital
Drachten, Friesland, Netherlands
Antonius Hospital
Sneek, Friesland, Netherlands
Rijnstate Hospital
Arnhem, Gelderland, Netherlands
Slingeland Hospital
Doetinchem, Gelderland, Netherlands
Isala klinieken
Zwolle, Overijssel, Netherlands
University Medical Centre Groningen
Groningen, Netherlands
Sponsors and Collaborators
Rijnstate Hospital
Investigators
Principal Investigator: MMJP Reijnen, MD, PhD Rijnstate Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Michel Reijnen, Principal Investigator, Rijnstate Hospital
ClinicalTrials.gov Identifier: NCT01220245     History of Changes
Other Study ID Numbers: 721-070910
Study First Received: October 11, 2010
Last Updated: April 10, 2017

Keywords provided by Michel Reijnen, Rijnstate Hospital:
endoluminal
surgical
bypass
patency
quality of life
multicentre
RCT
superficial femoral artery
vascular patency

Additional relevant MeSH terms:
Cardiovascular Diseases
Calcium heparin
Heparin
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 25, 2017